Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.03), Zacks reports. Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%.
Werewolf Therapeutics Price Performance
HOWL stock traded down $0.01 during trading on Friday, reaching $1.20. 251,631 shares of the company were exchanged, compared to its average volume of 270,648. The company has a 50-day moving average of $1.35 and a two-hundred day moving average of $1.80. The company has a market capitalization of $53.48 million, a price-to-earnings ratio of -0.78 and a beta of 0.37. Werewolf Therapeutics has a twelve month low of $1.03 and a twelve month high of $6.89. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10.
Analysts Set New Price Targets
Several equities analysts have recently commented on the stock. Wedbush restated an "outperform" rating and issued a $8.00 target price on shares of Werewolf Therapeutics in a research report on Wednesday. JMP Securities dropped their target price on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a "market outperform" rating for the company in a research report on Tuesday, January 14th. Finally, HC Wainwright restated a "buy" rating and issued a $15.00 target price on shares of Werewolf Therapeutics in a research report on Wednesday.
Check Out Our Latest Research Report on HOWL
Werewolf Therapeutics Company Profile
(
Get Free Report)
Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
Featured Articles
Before you consider Werewolf Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Werewolf Therapeutics wasn't on the list.
While Werewolf Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
